conatumumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 460106777

| image =

| type = mab

| mab_type = mab

| source = u

| target = TRAIL-R2 (CD262)

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 896731-82-1

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 1P48L61KM0

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09329

| C=6466 | H=10006 | N=1730 | O=2024 | S=40

| synonyms = anti-TRAIL receptor 2 monoclonal antibody, AMG-655

}}

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.{{cite journal | vauthors = Rosevear HM, Lightfoot AJ, Griffith TS | title = Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer | journal = Current Opinion in Investigational Drugs | location = London, England | volume = 11 | issue = 6 | pages = 688–98 | date = June 2010 | pmid = 20496264 | doi = }}{{cite journal | vauthors = Bajaj M, Heath EI | title = Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults | journal = Expert Opinion on Biological Therapy | volume = 11 | issue = 11 | pages = 1519–24 | date = November 2011 | pmid = 21877997 | doi = 10.1517/14712598.2011.610788 | s2cid = 28520935 }} Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[http://www.ama-assn.org/ama1/pub/upload/mm/365/conatumumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab], American Medical Association.[http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=573083 National Cancer Institute: Definition of conatumomab]

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.